Drug intelligence / Profile preview

dihexazin

Development stage
Unknown
Lead developer
Laboratorios Juste
Modality
Small Molecules
Administration
Oral, Sublingual
01

Overview

Dihexazin is a small molecule active pharmaceutical ingredient (API) developed and manufactured by Laboratorios Juste (Grupo Juste), a Spanish pharmaceutical company specializing in radiology and contrast media. It is classified as a contrast media agent intended for use in diagnostic imaging applications. The compound has a molecular formula of C50H52N3O6P and a molecular weight of approximately 821.94. As an API in Grupo Juste's portfolio, it is part of their established line of specialty chemicals for the diagnostic imaging market. While its specific clinical applications and detailed mechanism of action are not widely publicized, it is listed as an approved product within the company's chemical and pharmaceutical ingredient offerings.

Brand names
Dihexazin
Other names
CAS 2182626-95-3CAS2182626-95-3CAS-2182626-95-3
02

Targets

HTR2B (5-Hydroxytryptamine Receptor 2B)HTR2C (5-hydroxytryptamine 2C receptor)HTR2A (Serotonin receptor 5-HT2A)HRH1 (Histamine H1 Receptor)SPHK2 (Sphingosine kinase 2)HTR7 (5-hydroxytryptamine receptor 7)HRH2 (Histamine H2 Receptor)M1 (Muscarinic acetylcholine receptor M1)

Beyond the preview

Go deeper on dihexazin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dihexazin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call